Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, focuses on precision oncology, specifically developing small molecule TERN-701 for chronic myeloid leukemia (CML) [3][4] - TERN-701 has shown unprecedented efficacy, demonstrating 2-3 times the efficacy compared to other agents with a differentiated safety profile [3][12] Industry Context - The chronic myeloid leukemia (CML) market has a significant unmet need, particularly in patients who do not achieve major molecular response (MMR) [5][4] - Current treatments, including imatinib and asciminib, have limitations, with over 75% of patients not responding adequately to the best available therapies [5][6] Key Findings from Recent Data - TERN-701 achieved a 75% MMR in patients at doses of 320 mg and above, with deep molecular response rates exceeding 30% [11][12] - The safety profile of TERN-701 is favorable, with low rates of cytopenias and no significant adverse events compared to asciminib [12][13] - TERN-701 has shown efficacy in asciminib-refractory patients, a critical indicator of its potential superiority [15][27] Competitive Landscape - Asciminib has gained approximately 25% market share in the frontline setting, with expectations to reach 50% [6][7] - TERN-701 is positioned as a potential best-in-disease drug due to its efficacy, safety, and lack of food effect, which is crucial for patient adherence [27][40] - The company anticipates that TERN-701 will outperform asciminib in frontline settings, where newly diagnosed patients are generally easier to treat [32][40] Development Plans - Terns Pharmaceuticals plans to conduct a registrational study for TERN-701 in a second-line plus population, with a control arm of a physician's choice 2GTKI [84][86] - A frontline study is also planned, potentially comparing TERN-701 against imatinib or asciminib [86][88] - The company aims to finalize dose selection and engage with the FDA for guidance on study design by mid-2026 [43][82] Financial Position - Terns Pharmaceuticals has secured funding that positions it well for commercialization and launch of TERN-701 in the second-line plus setting [93][94] Additional Insights - The absence of a food effect with TERN-701 is a significant advantage, as many patients struggle with dietary restrictions associated with other therapies [49][55] - The company is exploring a mutation-specific cohort in its studies to address patients with specific genetic mutations, such as T315I [66][72] Conclusion - Terns Pharmaceuticals is poised to make a significant impact in the CML treatment landscape with TERN-701, addressing critical unmet needs and positioning itself against established therapies like asciminib and imatinib. The upcoming studies and FDA interactions will be pivotal in shaping the future of TERN-701 in the market [40][93]

Summary of Terns Pharmaceuticals Conference Call Company Overview - **Company**: Terns Pharmaceuticals - **Product**: Tern 701, an investigational next-generation oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment [2][41] Industry Context - **Disease**: Chronic Myeloid Leukemia (CML) - **Current Treatments**: First-generation and second-generation active-site tyrosine kinase inhibitors (TKIs) like Imatinib and Asciminib - **Market Need**: Significant unmet need for improved efficacy, safety, and tolerability in CML treatments, with approximately 40% of patients switching therapies within five years due to inadequate response or side effects [4][5] Key Points from the Call Efficacy and Safety Data - **Tern 701 Efficacy**: - Achieved a 75% major molecular response (MMR) and 36% deep molecular response (DMR) at 24 weeks in the recommended phase two dose range of 320 mg and above [8][31] - In a refractory patient population, 64% MMR was achieved by 24 weeks across all doses, with 75% MMR in patients at higher doses [10][22] - DMR rates are approximately two times higher than those seen with Asciminib [22][34] - **Safety Profile**: - Most treatment-emergent adverse events (AEs) were low-grade, with all grade three AEs being less than 10% [8][41] - No signs of pancreatic toxicity or significant blood pressure changes were observed, differentiating Tern 701 from Asciminib [18][41] Competitive Landscape - **Asciminib**: - First allosteric BCR-ABL inhibitor approved for CML, achieving a 22% market share in the U.S. within three quarters of launch and peak sales estimates revised to over $4 billion [5][6] - Tern 701 is positioned to potentially outperform Asciminib based on early clinical data [6][34] Clinical Trial Insights - **Cardinal Study**: - A two-part multicenter global study enrolling patients with chronic phase CML who have failed prior TKIs [12] - Enrollment has accelerated, with over 85 patients currently participating [3][41] Future Development Plans - **Next Steps**: - Plans to select a single dose for pivotal studies based on ongoing data collection and regulatory feedback [38][41] - Anticipated catalysts include expanded long-term data from the Cardinal study and potential regulatory meetings in 2026 [42][41] Market Opportunity - **Patient Population**: - Approximately 17,000 new CML patients annually in G7 nations, with a significant portion expected to switch to allosteric therapies due to better efficacy and tolerability [39][40] - **Treatment Goals**: - Focus on achieving rapid and deep molecular responses to improve long-term outcomes and quality of life for CML patients [39][52] Conclusion - Tern 701 shows promising efficacy and safety data, positioning it as a potential best-in-disease therapy for CML, with ongoing trials and future studies aimed at confirming its clinical benefits and market potential [41][42]

TERN-701 Efficacy and Safety - TERN-701 demonstrated a 64% Major Molecular Response (MMR) achievement rate at 24 weeks across all doses in non-T315I CP-CML patients (N=38)[20, 26] - At doses ≥320 mg QD, TERN-701 achieved a 75% MMR rate and a 36% Deep Molecular Response (DMR) rate at 24 weeks[18, 26, 75] - The majority of Treatment-Emergent Adverse Events (TEAEs) were low grade, with Grade 3 AEs less than 10%[18, 26] - No Dose Limiting Toxicities (DLTs) were observed, and the Maximum Tolerated Dose (MTD) was not identified[26, 37] - The study observed no pancreatic toxicity or clinically significant changes in blood pressure[18, 26] Patient Population and Treatment - The CARDINAL study enrolled a predominantly 3L+ refractory CML population (N=63 as of September 13, 2025)[24] - 38% of patients had prior asciminib treatment, with 75% of those discontinuing due to lack of efficacy[26, 33] - 87% of patients remained on treatment with a median treatment duration of 6.1 months[35] Competitive Landscape and Future Development - Asciminib NBRx share in 2L is 52% and in 3L+ is 53%[7] - Asciminib NBRx share of front-line is 22%[7] - TERN-701 is positioned to potentially capture new patients and switch from both Asciminib and Active Site TKIs[103] - Multiple catalysts are planned in 2026, including expanded CARDINAL data, pivotal dose selection, and alignment with regulators for pivotal studies[99, 106]

Summary of Terns Pharmaceuticals Conference Call Company Overview - **Company**: Terns Pharmaceuticals (NasdaqGS:TERN) - **Event**: 2025 Conference on November 17, 2025 Key Industry Insights - **Industry**: Pharmaceuticals and Biotechnology, specifically focusing on treatments for Chronic Myeloid Leukemia (CML) Core Points and Arguments 1. **Efficacy of TERN-701**: Terns reported a major molecular response rate of 64% in highly refractory CML patients during their phase one study, which is unprecedented compared to the previous best of 32% in similar studies [2][4][5] 2. **Safety Profile**: The safety profile of TERN-701 is favorable, with only one discontinuation due to an adverse event noted in the trial [2][4] 3. **Food Effect**: TERN-701 does not exhibit a food effect, allowing for dosing without regard to food intake, which is a significant advantage over competitors like asciminib [2][8] 4. **Collaboration with Hansoh**: Terns has a partnership with Hansoh in China, which has provided additional data that supports TERN-701's development, although Terns primarily relies on its own data for future trials [4][12] 5. **Comparative Analysis with Asciminib**: Terns believes that TERN-701's distinct chemical properties and binding characteristics lead to enhanced efficacy compared to asciminib, which has shown a lower response rate and higher discontinuation rates [5][8][9] 6. **Clinical Development Strategy**: Terns plans to initiate pivotal trials for TERN-701, focusing first on second-line treatments before moving to first-line studies, with the aim of running both studies in parallel [20][18] 7. **Market Opportunity**: The management team believes that the long-term market opportunity for TERN-701 extends beyond asciminib-refractory patients, emphasizing the importance of understanding patient history and disease burden [13][14] 8. **Regulatory Pathway**: Terns aims to follow a similar regulatory pathway to asciminib, targeting both second-generation treatments and imatinib in first-line studies [18][20] 9. **Financial Considerations**: The estimated direct costs for pivotal trials are under $100 million for second-line studies and under $150 million for first-line studies, indicating a more manageable financial requirement than initially anticipated [29] 10. **Future Data Expectations**: The upcoming ASH presentation is expected to provide more detailed data, including a shift table that will illustrate patient responses across different categories, which is crucial for understanding the drug's efficacy [31][32] Additional Important Insights - **Cure Potential**: The concept of treatment-free remission in CML is discussed, with TERN-701 potentially leading to faster and deeper responses that could facilitate this outcome [25][27] - **Enrollment Trends**: There has been a notable increase in enrollment rates for clinical trials, attributed to the positive reception of TERN-701's data among clinicians [33][34] - **Cash Position**: Terns has sufficient cash reserves to fund operations into 2028, allowing for strategic planning without immediate pressure to raise additional funds [40] This summary encapsulates the critical insights and strategic direction of Terns Pharmaceuticals as discussed in the conference call, highlighting the potential of TERN-701 in the competitive landscape of CML treatments.